Cargando…

Polipharmacy and Multimorbity in Oncological Patients: An Open Challenge

Kirkham and colleagues presented an original study about cancer survivors in Canadian population and reported that the odds of several cardiovascular disease risk factors are higher among middle-aged. Several risk factors are connected to a toxic lifestyle and are associated with cardiovascular dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Loreti, Claudia, Castelli, Letizia, Coraci, Daniele, Fusco, Augusto, Giovannini, Silvia, Padua, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985765/
http://dx.doi.org/10.3390/curroncol28010030
_version_ 1783668317476618240
author Loreti, Claudia
Castelli, Letizia
Coraci, Daniele
Fusco, Augusto
Giovannini, Silvia
Padua, Luca
author_facet Loreti, Claudia
Castelli, Letizia
Coraci, Daniele
Fusco, Augusto
Giovannini, Silvia
Padua, Luca
author_sort Loreti, Claudia
collection PubMed
description Kirkham and colleagues presented an original study about cancer survivors in Canadian population and reported that the odds of several cardiovascular disease risk factors are higher among middle-aged. Several risk factors are connected to a toxic lifestyle and are associated with cardiovascular diseases and general health status. The paper is very relevant in managing oncological patients. A particular attention should be given to some anamnestic data about the presence of other pathologies (as self-reported diabetes and hypertension) and drug therapy with particular consideration of angiotensin-converting enzyme inhibitors that present a protective action against cardiovascular events and reduce the incidence of type II diabetes. In order to identify and intervene on risk factors, clinicians should depict the pharmacological therapy taken by the study population, assuming that in the elderly this may be potentially protective on cardiovascular risk profile compared to younger cancer survivors.
format Online
Article
Text
id pubmed-7985765
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79857652021-03-24 Polipharmacy and Multimorbity in Oncological Patients: An Open Challenge Loreti, Claudia Castelli, Letizia Coraci, Daniele Fusco, Augusto Giovannini, Silvia Padua, Luca Curr Oncol Comment Kirkham and colleagues presented an original study about cancer survivors in Canadian population and reported that the odds of several cardiovascular disease risk factors are higher among middle-aged. Several risk factors are connected to a toxic lifestyle and are associated with cardiovascular diseases and general health status. The paper is very relevant in managing oncological patients. A particular attention should be given to some anamnestic data about the presence of other pathologies (as self-reported diabetes and hypertension) and drug therapy with particular consideration of angiotensin-converting enzyme inhibitors that present a protective action against cardiovascular events and reduce the incidence of type II diabetes. In order to identify and intervene on risk factors, clinicians should depict the pharmacological therapy taken by the study population, assuming that in the elderly this may be potentially protective on cardiovascular risk profile compared to younger cancer survivors. MDPI 2021-01-04 /pmc/articles/PMC7985765/ http://dx.doi.org/10.3390/curroncol28010030 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Comment
Loreti, Claudia
Castelli, Letizia
Coraci, Daniele
Fusco, Augusto
Giovannini, Silvia
Padua, Luca
Polipharmacy and Multimorbity in Oncological Patients: An Open Challenge
title Polipharmacy and Multimorbity in Oncological Patients: An Open Challenge
title_full Polipharmacy and Multimorbity in Oncological Patients: An Open Challenge
title_fullStr Polipharmacy and Multimorbity in Oncological Patients: An Open Challenge
title_full_unstemmed Polipharmacy and Multimorbity in Oncological Patients: An Open Challenge
title_short Polipharmacy and Multimorbity in Oncological Patients: An Open Challenge
title_sort polipharmacy and multimorbity in oncological patients: an open challenge
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985765/
http://dx.doi.org/10.3390/curroncol28010030
work_keys_str_mv AT loreticlaudia polipharmacyandmultimorbityinoncologicalpatientsanopenchallenge
AT castelliletizia polipharmacyandmultimorbityinoncologicalpatientsanopenchallenge
AT coracidaniele polipharmacyandmultimorbityinoncologicalpatientsanopenchallenge
AT fuscoaugusto polipharmacyandmultimorbityinoncologicalpatientsanopenchallenge
AT giovanninisilvia polipharmacyandmultimorbityinoncologicalpatientsanopenchallenge
AT padualuca polipharmacyandmultimorbityinoncologicalpatientsanopenchallenge